keyword
MENU ▼
Read by QxMD icon Read
search

Chemotherapy neurotoxicity

keyword
https://www.readbyqxmd.com/read/28320152/electrographic-patterns-in-patients-with-posterior-reversible-encephalopathy-syndrome-and-seizures
#1
Carlos Kamiya-Matsuoka, Sudhakar Tummala
INTRODUCTION: Posterior reversible encephalopathy syndrome (PRES) is a neurotoxic encephalopathic state associated with reversible cerebral vasogenic edema. Seizures are a common clinical presentation in PRES, however its electroencephalographic and radiologic pattern correlation is limited in this subset of patients. The aim of this study is to analyze the origin of electrographic dysfunction according to the radiologic pattern in patients with PRES and seizures. METHODS: We retrospectively identified 46 cancer patients who developed PRES and seizures at The University of Texas MD Anderson Cancer Center between January 2006 and June 2012...
April 15, 2017: Journal of the Neurological Sciences
https://www.readbyqxmd.com/read/28290072/changes-in-brain-white-matter-integrity-after-systemic-treatment-for-breast-cancer-a-prospective-longitudinal-study
#2
Sanne Menning, Michiel B de Ruiter, Dick J Veltman, Willem Boogerd, Hester S A Oldenburg, Liesbeth Reneman, Sanne B Schagen
An increasing number of studies suggest chemotherapy for breast cancer may be neurotoxic. Cross-sectional MRI diffusion tensor imaging (DTI) studies suggest a vulnerability of brain white matter to various chemotherapeutic regimens. Up till now, this was confirmed in one prospective DTI study: Deprez et al. (2012) showed a widespread decline in fractional anisotropy (FA) of breast cancer patients after chemotherapy consisting of 5-fluorouracil (5-FU), epirubicin and cyclophosphamide (FEC) +/- taxanes +/- endocrine treatment...
March 13, 2017: Brain Imaging and Behavior
https://www.readbyqxmd.com/read/28286483/long-term-effects-pathophysiological-mechanisms-and-risk-factors-of-chemotherapy-induced-peripheral-neuropathies-a-comprehensive-literature-review
#3
REVIEW
Nicolas Kerckhove, Aurore Collin, Sakahlé Condé, Carine Chaleteix, Denis Pezet, David Balayssac
Neurotoxic anticancer drugs, such as platinum-based anticancer drugs, taxanes, vinca alkaloids, and proteasome/angiogenesis inhibitors are responsible for chemotherapy-induced peripheral neuropathy (CIPN). The health consequences of CIPN remain worrying as it is associated with several comorbidities and affects a specific population of patients already impacted by cancer, a strong driver for declines in older adults. The purpose of this review is to present a comprehensive overview of the long-term effects of CIPN in cancer patients and survivors...
2017: Frontiers in Pharmacology
https://www.readbyqxmd.com/read/28286117/carvedilol-prevents-functional-deficits-in-peripheral-nerve-mitochondria-of-rats-with-oxaliplatin-evoked-painful-peripheral-neuropathy
#4
Aparna Areti, Prashanth Komirishetty, Ashutosh Kumar
Oxaliplatin use as chemotherapeutic agent is frequently limited by cumulative neurotoxicity which may compromise quality of life. Reports relate this neurotoxic effect to oxidative stress and mitochondrial dysfunction in peripheral nerves and dorsal root ganglion (DRG). Carvedilol is an antihypertensive drug, has also been appreciated for its antioxidant and mitoprotective properties. Carvedilol co-treatment did not reduce the anti-tumor effects of oxaliplatin in human colon cancer cells (HT-29), but exhibited free radical scavenging activity against oxaliplatin-induced oxidative stress in neuronal cells (Neuro-2a)...
March 9, 2017: Toxicology and Applied Pharmacology
https://www.readbyqxmd.com/read/28281024/retinal-toxicity-after-cisplatin-based-chemotherapy-in-patients-with-germ-cell-cancer
#5
Simon Dulz, Niels H Asselborn, Klaus-Peter Dieckmann, Cord Matthies, Walter Wagner, Jens Weidmann, Christoph Seidel, Christoph Oing, Lars A Berger, Winfried Alsdorf, Blanche Mankichian, Christian Meyer, Malte W Vetterlein, Philipp Gild, Tim A Ludwig, Armin Soave, Philipp Schriefer, Andreas Becker, Sascha A Ahyai, Karin Oechsle, Carsten Bokemeyer, Lars Wagenfeld, Margit Fisch, Michael Hartmann, Felix K-H Chun, Luis A Kluth
PURPOSE: Visual impairment represents an infrequent form of cisplatin-induced neurotoxicity; however, visual deterioration has been reported in several studies. To evaluate potential morphological and functional retinal alterations in patients with germ cell cancer (GCC) treated with cisplatin-based chemotherapy (CBC). METHODS: Multi-disciplinary and multi-institutional study design. Examination of 28 eyes of 14 male GCC patients, who had received at least one cycle of CBC...
March 9, 2017: Journal of Cancer Research and Clinical Oncology
https://www.readbyqxmd.com/read/28280368/evidence-from-a-meta-analysis-is-nivolumabneurotoxic-in-cancer-patients
#6
Xiangyi Kong, Yanguo Kong
The aim of this study was to summarize the findings of previous studies focusing on whether the risks of certain neurotoxicities are correlated to the programmed death 1 (PD-1) inhibitor nivolumab versus other chemotherapy or immunotherapy drugs. Six eligible studies, including 3,023 patients, were considered in the meta-analysis. The risk ratios (RRs) of fatigue, headache, dysgeusia, vertigo, paresthesia, anxiety or malaise and peripheral neuropathy were 0.908 (95% confidence interval [95% CI]: 0.724, 1.138; P=0...
2017: OncoTargets and Therapy
https://www.readbyqxmd.com/read/28267750/changes-in-brain-activation-in-breast-cancer-patients-depend-on-cognitive-domain-and-treatment-type
#7
Sanne Menning, Michiel B de Ruiter, Dick J Veltman, Willem Boogerd, Hester S A Oldenburg, Liesbeth Reneman, Sanne B Schagen
BACKGROUND: Cognitive problems in breast cancer patients are common after systemic treatment, particularly chemotherapy. An increasing number of fMRI studies show altered brain activation in breast cancer patients after treatment, suggestive of neurotoxicity. Previous prospective fMRI studies administered a single cognitive task. The current study employed two task paradigms to evaluate whether treatment-induced changes depend on the probed cognitive domain. METHODS: Participants were breast cancer patients scheduled to receive systemic treatment (anthracycline-based chemotherapy +/- endocrine treatment, n = 28), or no systemic treatment (n = 24) and no-cancer controls (n = 31)...
2017: PloS One
https://www.readbyqxmd.com/read/28265863/examining-the-impact-of-a-web-based-intervention-to-promote-patient-activation-in-chemotherapy-induced-peripheral-neuropathy-assessment-and-management
#8
Robert Knoerl, Deborah Lee, James Yang, Celia Bridges, Grace Kanzawa-Lee, G Lita Smith, Ellen M Lavoie Smith
Lack of activation in self-care can compromise a patient's ability to monitor and manage cancer treatment-related side effects, such as chemotherapy-induced peripheral neuropathy (CIPN). The web-based Carevive® Care Planning System (CPS) was developed to promote evidence-based symptom assessment and treatment by enhancing patients' involvement in their own care. The purpose of this single-arm, pre-test/post-test, prospective study was to examine whether the CPS can promote patient activation in CIPN symptom assessment and management...
March 6, 2017: Journal of Cancer Education: the Official Journal of the American Association for Cancer Education
https://www.readbyqxmd.com/read/28205185/use-of-an-alpha-lipoic-methylsulfonylmethane-and-bromelain-dietary-supplement-opera-%C3%A2-for-chemotherapy-induced-peripheral-neuropathy-management-a-prospective-study
#9
Isacco Desideri, Giulio Francolini, Carlotta Becherini, Francesca Terziani, Camilla Delli Paoli, Emanuela Olmetto, Mauro Loi, Marco Perna, Icro Meattini, Vieri Scotti, Daniela Greto, Pierluigi Bonomo, Susanna Sulprizio, Lorenzo Livi
Chemotherapy-induced peripheral neuropathy (CIPN) is a major clinical problem associated with a number of cytotoxic agents. OPERA(®) (GAMFARMA srl, Milan, Italy) is a new dietary supplement where α-lipoic acid, Boswellia Serrata, methylsulfonylmethane and bromelain are combined in a single capsule. The aim of this prospective study was to determine the efficacy and safety of OPERA(®) supplementation in a series of patients affected by CIPN. We selected 25 subjects with CIPN evolving during or after chemotherapy with potentially neurotoxic agents...
March 2017: Medical Oncology
https://www.readbyqxmd.com/read/28194052/once-weekly-1-6%C3%A2-mg-m-2-bortezomib-bcd-regimen-in-elderly-patients-with-newly-diagnosed-multiple-myeloma-who-are-unfit-for-standard-dose-chemotherapy
#10
Yong Tang, Ye-Hua Yu, Yi-Yun Yao, Li-Fang Zou, Hong-Ju Dou, Lei Wang, Qi Zhu
Bortezomib has shown anti-myeloma effects in combination with alkylating agents, but clinical benefits can be limited by neurotoxicity. There is less information on the efficacy and tolerability of once-weekly 1.6 mg/m(2) bortezomib combined with cyclophosphamide and dexamethasone (BCD) regimen in elderly patients with newly diagnosed multiple myeloma who are unfit for standard dose chemotherapy. Here, we report our experience of weekly 1.6 mg/m(2) intravenous bortezomib in this group of patients. Between March 2010 and February 2015, we treated 34 newly diagnosed elderly patients with the combination of bortezomib 1...
March 2017: Indian Journal of Hematology & Blood Transfusion
https://www.readbyqxmd.com/read/28169156/posterior-reversible-encephalopathy-syndrome-associated-with-dose-adjusted-epoch-etoposide-prednisone-vincristine-cyclophosphamide-doxorubicin-chemotherapy
#11
Abby E Floeter, Amila Patel, Melinda Tran, Marc C Chamberlain, Paul C Hendrie, Ajay K Gopal, Ryan D Cassaday
INTRODUCTION: The purpose of our study was to identify the key risk factors for the development of posterior reversible encephalopathy syndrome (PRES) after administration of the combination chemotherapy regimen, DA-EPOCH (dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin). MATERIALS AND METHODS: We performed a retrospective medical record review of patients receiving DA-EPOCH with or without rituximab (DA-EPOCH ± R) at our institution from July 2012 to September 2014...
January 10, 2017: Clinical Lymphoma, Myeloma & Leukemia
https://www.readbyqxmd.com/read/28160544/effects-of-hypericum-perforatum-extract-on-oxaliplatin-induced-neurotoxicity-in-vitro-evaluations
#12
Lorenzo Cinci, Lorenzo Di Cesare Mannelli, Anna Maidecchi, Luisa Mattoli, Carla Ghelardini
Hypericum perforatum L. has been used for centuries as a natural remedy for the treatment of many disorders. Neuropathic pain is a common side effect of oxaliplatin-based chemotherapy and often the cause of therapy discontinuation. Thanks to its anti-inflammatory and analgesic effects, the use of H. perforatum may be a novel therapeutic strategy for neuropathy. The aim of this paper was to evaluate the effect of H. perforatum hydrophilic extract on an in vitro model of oxaliplatin-induced neurotoxicity. The antioxidant potential of extract was first evaluated in cell-free models by the thiobarbituric acid-reactive substances assay and nitro blue tetrazolium oxidation test; the ability of H...
February 4, 2017: Zeitschrift Für Naturforschung. C, A Journal of Biosciences
https://www.readbyqxmd.com/read/28156643/pilot-study-of-minocycline-for-the-prevention-of-paclitaxel-associated-neuropathy-accru-ru221408i
#13
Travis J Dockter, Patricia J Zekan, Briant Fruth, Kathryn Jean Ruddy, Lauren E Ta, Todor Dentchev, Nguyet Le-Lindqwister, William M Sikov, Charles L Loprinzi
220 Background: Paclitaxel is associated with both an acute pain syndrome (P-APS) and chronic chemotherapy-induced peripheral neuropathy (CIPN). Preliminary animal data suggest that minocycline may be effective for the prevention of chemotherapy-induced neurotoxicity. The purpose of this pilot study was to investigate the efficacy of minocycline for the prevention of CIPN and P-APS. METHODS: Patients with breast cancer were enrolled prior to initiating neoadjuvant or adjuvant weekly paclitaxel for 12 weeks...
October 9, 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28139029/vincristine-induced-peripheral-neuropathy-in-survivors-of-childhood-acute-lymphoblastic-leukaemia
#14
Chee Geap Tay, Vanessa Wan Mun Lee, Lai Choo Ong, Khean Jin Goh, Hany Ariffin, Choong Yi Fong
BACKGROUND: Vincristine, an essential component of childhood acute lymphoblastic leukaemia (ALL) therapeutic protocols, is associated with dose-dependent neurotoxicity, but its long-term morbidity in treated children has not been clearly elucidated. The aim of this study is to determine the prevalence of vincristine-induced peripheral neuropathy (VIPN) among Malaysian childhood ALL survivors and its impact on motor function and quality of life. PROCEDURE: Survivors of childhood ALL aged 4-18 years who had completed chemotherapy for 2 years or more were evaluated for VIPN using both the clinical Total Neuropathy Score (cTNS) and nerve conduction studies...
January 31, 2017: Pediatric Blood & Cancer
https://www.readbyqxmd.com/read/28130818/neurocognitive-outcomes-among-children-who-experienced-seizures-during-treatment-for-acute-lymphoblastic-leukemia
#15
Stephanie L Nassar, Heather M Conklin, Yinmei Zhou, Jason M Ashford, Wilburn E Reddick, John O Glass, Fred H Laningham, Sima Jeha, Cheng Cheng, Ching-Hon Pui
BACKGROUND: Limited information is available regarding neurocognitive outcomes of children who experience seizures during treatment for acute lymphoblastic leukemia (ALL). Accordingly, the main objectives of this study were to determine the incidence and risk factors for treatment-related seizures among children with ALL, and the neurocognitive outcomes associated with treatment-related seizures. PROCEDURE: Prospective neuropsychological assessment and magnetic resonance imaging (MRI) were planned for all 498 patients with newly diagnosed ALL enrolled on the St...
January 28, 2017: Pediatric Blood & Cancer
https://www.readbyqxmd.com/read/28129122/phase-1-results-of-zuma-1-a-multicenter-study-of-kte-c19-anti-cd19-car-t-cell-therapy-in-refractory-aggressive-lymphoma
#16
Frederick L Locke, Sattva S Neelapu, Nancy L Bartlett, Tanya Siddiqi, Julio C Chavez, Chitra M Hosing, Armin Ghobadi, Lihua E Budde, Adrian Bot, John M Rossi, Yizhou Jiang, Allen X Xue, Meg Elias, Jeff Aycock, Jeff Wiezorek, William Y Go
Outcomes for patients with refractory diffuse large B cell lymphoma (DLBCL) are poor. In the multicenter ZUMA-1 phase 1 study, we evaluated KTE-C19, an autologous CD3ζ/CD28-based chimeric antigen receptor (CAR) T cell therapy, in patients with refractory DLBCL. Patients received low-dose conditioning chemotherapy with concurrent cyclophosphamide (500 mg/m(2)) and fludarabine (30 mg/m(2)) for 3 days followed by KTE-C19 at a target dose of 2 × 10(6) CAR T cells/kg. The incidence of dose-limiting toxicity (DLT) was the primary endpoint...
January 4, 2017: Molecular Therapy: the Journal of the American Society of Gene Therapy
https://www.readbyqxmd.com/read/28127506/chemotherapy-induced-neuropathies-a-growing-problem-for-patients-and-health-care-providers
#17
Marta Banach, Judyta K Juranek, Aneta L Zygulska
INTRODUCTION: Chemotherapy-induced neuropathies are one of the most common side effects of cancer treatment, surpassing bone marrow suppression and kidney dysfunction. Chemotherapy effects on the nervous system vary between different classes of drugs and depend on specific chemical and physical properties of the drug used. The three most neurotoxic classes of anti-cancer drugs are: platinum-based drugs, taxanes, and thalidomide and its analogs; other, less neurotoxic but also commonly used drugs are: bortezomib, ixabepilone, and vinca alkaloids...
January 2017: Brain and Behavior
https://www.readbyqxmd.com/read/28116479/the-magnitude-of-neurotoxicity-in-patients-with-multiple-myeloma-and-the-impact-of-dose-modifications-results-from-the-population-based-profiles-registry
#18
Antoinetta J M Beijers, Simone Oerlemans, Floortje Mols, Marijke Eurelings, Monique C Minnema, Art Vreugdenhil, Lonneke V van de Poll-Franse
The aim of this analysis is to assess (1) self-reported chemotherapy-induced peripheral neuropathy (CIPN) symptoms; (2) its association with sociodemographic and clinical characteristics; and (3) treatment dose modifications and its influence on the magnitude of neurotoxicity in a population-based cohort of patients with multiple myeloma (MM). MM patients (n = 156), diagnosed between 2000 and 2014, filled out the EORTC QLQ-CIPN20 (65% response). Data on treatment, outcomes, and dose modifications were extracted from the medical files...
April 2017: Annals of Hematology
https://www.readbyqxmd.com/read/28104535/immune-mediated-processes-implicated-in-chemotherapy-induced-peripheral-neuropathy
#19
REVIEW
Justin G Lees, Preet G S Makker, Ryan S Tonkin, Munawwar Abdulla, Susanna B Park, David Goldstein, Gila Moalem-Taylor
Chemotherapy-induced peripheral neuropathy (CIPN) and associated neuropathic pain are challenging complications of cancer treatment. Many of the major classes of chemotherapeutics can cause neurotoxicity and significantly modulate the immune system. There is ongoing investigation regarding whether reciprocal crosstalk between the nervous and immune systems occurs and, indeed, contributes to neuropathic pain during treatment with chemotherapeutics. An emerging concept is that neuroinflammation is one of the major mechanisms underlying CIPN...
March 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/28104300/challenges-and-opportunities-in-primary-cns-lymphoma-a-systematic-review
#20
REVIEW
Mariana N Kerbauy, Fabio Y Moraes, Benjamin H Lok, Jennifer Ma, Lucila N Kerbauy, Daniel E Spratt, Fabio P S Santos, Guilherme F Perini, Alejandro Berlin, Caroline Chung, Nelson Hamerschlak, Joachim Yahalom
BACKGROUND: Historically, high-dose methotrexate (HD-MTX) plus consolidation chemotherapy and/or whole brain radiotherapy (WBRT) has been the gold standard on Primary Central Nervous System Lymphoma (PCNSL) management. We sought to examine and summarize the data, on clinical trial (CT) setting, investigating multi-modality treatment to PCNSL. METHODS: We performed a systematic review of electronic databases (Medline, EMBASE, Cochrane Database and clinicaltrials...
January 16, 2017: Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology
keyword
keyword
99779
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"